NCT04599543

Clinical Trial for the Safety and Efficacy of IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

Study Summary

A Study of IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia.

Interested in this trial?

Submit an Inquiry

IL3 CAR T-cellsDRUG

Each subject receive IL3 CAR T-cells by intravenous infusion

Facility	City	State	Country
The First Affiliated Hospital，College of Medicine, Zhejiang University	Hangzhou	Zhejiang	China

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026